Alan Norman Gibbs

US Patent:

20090155815, Jun 18, 2009

Filed:

Oct 24, 2008

Appl. No.:

12/258037

Inventors:

Bruce L. Grasberger - Trappe PA, US
Cynthia Milligan - Rutledge PA, US
John C. Spurlino - Downington PA, US
Ruth A. Steele - West Chester PA, US
Kenneth R. Singleton - Downington PA, US
Alan C. Gibbs - Wyndmoor PA, US
Francis A. Lewandowski - Washington Crossing PA, US

International Classification:

G01N 33/566
C12N 11/02

US Classification:

435 78, 435177

Abstract:

A crystallized human ACC2 CT protein as well as a description of the X-ray diffraction pattern of the crystal are disclosed. The diffraction pattern allows the three dimensional structure of human ACC2 CT to be determined at atomic resolution so that ligand binding sites on human ACC2 CT can be identified and the interactions of ligands with human ACC2 CT amino acid residues can be modeled. Models prepared using such maps permit the design of ligands which can function as active agents which include, but are not limited to, those that function as inhibitors of human ACC2 and human ACC1 proteins.

US Patent:

20110263559, Oct 27, 2011

Filed:

Apr 21, 2011

Appl. No.:

13/091344

Inventors:

Xuqing ZHANG - Spring House PA, US
Marta G. ABAD - Downingtown PA, US
Alan C. GIBBS - Wyndmoor PA, US
Lawrence C. KUO - Gwynedd Valley PA, US
Fengbin SONG - Princeton NJ, US
Zhihua SUI - Spring House PA, US

International Classification:

A61K 31/416
A61K 31/496
C07D 403/12
C07D 401/12
A61K 31/454
A61K 31/4439
C07D 487/08
A61K 31/551
C07D 401/14
C07D 487/04
A61K 31/519
C07D 471/04
A61K 31/4545
A61P 3/04
A61P 3/10
A61P 3/06
C07D 403/10

US Classification:

51421018, 544371, 51425406, 5483615, 546199, 514322, 514407, 5462757, 514338, 540575, 514218, 51421021, 544364, 51425309, 544262, 51425216, 546119, 514303

Abstract:

The present invention is directed to substituted indazole compounds, pharmaceutical compositions of these compounds and methods of use thereof. The compounds of the present invention are ketohexokinase (KHK) inhibitors, useful for treating or ameliorating a KHK mediated metabolic disorders and/or diseases such as obesity, Type II diabetes mellitus and Metabolic Syndrome X.